RxDoctor Payments Data

Michael Dulay

Family · Castleton, NYNPI 1528494317

Payments from drug & device makers

$6,634in general payments, 2019–2025

Across 321 payments — averaging $20.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Johnson & Johnson$978
  • Regeneron Healthcare Solutions, Inc.$678
  • Novartis$594
  • Lilly USA, LLC$521
  • E.r. Squibb & Sons, L.L.C.$409
  • plus $1K from 11 others

What the payments were for

  • Food & beverage$6,624100%
  • Education$100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,634 in reported general payments places this provider in the 95th percentile of 8,883 family providers in New York.

See all family providers in New York

Medicare billing

Part B allowed, 2024
$159,449
Medicare patients
782
Services billed
3,300

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Enbrel SureclickEtanercept13$94,777
OtezlaApremilast13$77,093
Dupixent PenDupilumab21$75,252
Clobetasol Propionate64$2,738
Ketoconazole96$2,717
Fluorouracil25$1,560
Doxycycline Hyclate88$1,284
Metronidazole23$1,185
Triamcinolone Acetonide82$1,088
Clindamycin Phosphate30$979
Cephalexin161$712
Betamethasone Diprop AugmentedBetamethasone/Propylene Glyc15$493
Hydroxychloroquine Sulfate16$443
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip28$406
ValacyclovirValacyclovir Hcl13$387

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$205$77,09313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,883 family providers in New York.

Other family in Castleton

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →